Were Methamphetamine-Associated PAH Patients Hemodynamically Worse Than Idiopathic PAH Patients?
A U.S. PAH Biobank analysis compared people classified with methamphetamine-associated pulmonary arterial hypertension (MA-PAH) with two other pulmonary arterial hypertension groups. Of 1,830 patients, 42 had MA-PAH, 1,073 had idiopathic PAH and 715 had connective-tissue-associated PAH.
What differed by comparison group
Mean pulmonary artery pressure and pulmonary vascular resistance in the MA-PAH group were similar to the idiopathic group, but higher than the connective-tissue-associated group. The authors did not detect a statistically significant difference in functional class among the three groups, and percent-predicted six-minute walking distance was comparable.
Why this is not an individual causation test
The study describes people already enrolled with PAH and compares group characteristics. It does not estimate the chance that a particular methamphetamine user will develop PAH, and the MA-PAH subgroup was small. Similarity to one comparison group does not imply identical disease mechanisms, prognosis or treatment response. The clinical label and the registry data should not replace a patient-specific exposure history and diagnostic assessment.
The supported conclusion is that hemodynamic severity in this registry sample depended on the comparison group: similar to idiopathic PAH on selected measures, higher than connective-tissue-associated PAH on others.
Source: Charoenpong P, et al. Methamphetamine-associated pulmonary arterial hypertension: data from the PAH Biobank. BMJ Open Respiratory Research. 2023;10:e001917. doi:10.1136/bmjresp-2023-001917.



